S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
S&P 500   5,123.41
DOW   37,983.24
QQQ   438.27
Stock market today: Wall Street falls sharply to close out its worst week since October
5 Semiconductor Giants: Navigating the Recent Pullback
2 Stocks to Buy on The Dip: One a Value, the Other High-Yielding
Breakout Alert: Coinbase's Consolidation Is About To End
3 Key Stocks Helping to Drive the EV Race
Closing prices for crude oil, gold and other commodities
You Can Follow BlackRock’s Market View for Your Money
NASDAQ:ACHL

Achilles Therapeutics (ACHL) Stock Price, News & Analysis

$0.85
0.00 (0.00%)
(As of 04/12/2024 ET)
Today's Range
$0.84
$0.86
50-Day Range
$0.82
$1.57
52-Week Range
$0.74
$1.76
Volume
163,969 shs
Average Volume
722,425 shs
Market Capitalization
$34.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Achilles Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
370.6% Upside
$4.00 Price Target
Short Interest
Healthy
0.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.34mentions of Achilles Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.34) to ($1.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.54 out of 5 stars

Medical Sector

2353rd out of 2,781 stocks

Biological Products, Except Diagnostic Industry

394th out of 465 stocks

ACHL stock logo

About Achilles Therapeutics Stock (NASDAQ:ACHL)

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

ACHL Stock Price History

ACHL Stock News Headlines

Achilles Therapeutics (NASDAQ:ACHL) Price Target Cut to $6.00
Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
ACHL Stock Earnings: Achilles Therapeutics Misses EPS for Q4 2023
Gold Hits New All-Time Highs
Due to both domestic and global issues, the trajectory of this precious metal could skyrocket in the coming months… Which is why billionaires and Central Banks alike are scooping up gold at record rates!
Achilles Therapeutics PLC ADR
Achilles Therapeutics PLC ADR (ACHL)
ACHL Achilles Therapeutics plc
See More Headlines
Receive ACHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/04/2023
Today
4/13/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ACHL
Fax
N/A
Employees
234
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$6.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+370.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-69,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.49 per share

Miscellaneous

Free Float
38,589,000
Market Cap
$34.66 million
Optionable
Not Optionable
Beta
1.09
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Iraj Ali Ph.D. (Age 49)
    CEO & Director
  • Dr. Karl Stuart Peggs M.D. (Age 57)
    Founder & Chief Medical Officer
  • Dr. Mark William Lowdell BSc (Age 61)
    FRCPath, MICR, MSc, Ph.D., Founder
  • Dr. Charles Swanton FMEDSCI (Age 51)
    M.D., Ph.D., Founder
  • Dr. Sergio A. Quezada Ph.D. (Age 48)
    Founder & Chief Scientific Officer
  • Mr. Robert Coutts (Age 40)
    Chief Financial Officer
  • Mr. Lee M. Stern
    Vice President of Investor Relations & External Communications
  • Mr. Daniel Carey Cazel Hood
    General Counsel & Company Secretary
  • Julia Wilson
    Head of Communications
  • Mr. Tariq Ahmed
    Executive Vice President of People

ACHL Stock Analysis - Frequently Asked Questions

Should I buy or sell Achilles Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Achilles Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ACHL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACHL, but not buy additional shares or sell existing shares.
View ACHL analyst ratings
or view top-rated stocks.

What is Achilles Therapeutics' stock price target for 2024?

3 brokers have issued twelve-month target prices for Achilles Therapeutics' shares. Their ACHL share price targets range from $2.00 to $6.00. On average, they predict the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 370.6% from the stock's current price.
View analysts price targets for ACHL
or view top-rated stocks among Wall Street analysts.

How have ACHL shares performed in 2024?

Achilles Therapeutics' stock was trading at $0.8890 at the start of the year. Since then, ACHL stock has decreased by 4.4% and is now trading at $0.85.
View the best growth stocks for 2024 here
.

Are investors shorting Achilles Therapeutics?

Achilles Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 74,800 shares, an increase of 8.6% from the March 15th total of 68,900 shares. Based on an average trading volume of 768,800 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.2% of the company's shares are sold short.
View Achilles Therapeutics' Short Interest
.

When is Achilles Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ACHL earnings forecast
.

How were Achilles Therapeutics' earnings last quarter?

Achilles Therapeutics plc (NASDAQ:ACHL) announced its quarterly earnings results on Friday, August, 4th. The company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.40) by $0.02.

When did Achilles Therapeutics IPO?

Achilles Therapeutics (ACHL) raised $176 million in an IPO on Wednesday, March 31st 2021. The company issued 9,800,000 shares at a price of $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. acted as the underwriters for the IPO.

How do I buy shares of Achilles Therapeutics?

Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACHL) was last updated on 4/13/2024 by MarketBeat.com Staff

From Our Partners